Drugs / CH505TF gp120
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05182125 | Nov 2021 → Aug 2023 | HIV infectious disease | HIV Vaccine Trials Network | Completed | No outcome recorded |
| Phase 1 | NCT04607408 | Nov 2020 → Jul 2024 | HIV infectious disease | HIV Vaccine Trials Network | Completed | No outcome recorded |
| Phase 1 | NCT03220724 | Aug 2017 → Mar 2023 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CH505TF gp120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05182125 ↗ |
| Known as | CH505TF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03220724 ↗ |
| Modality | Vaccine | “The three individual EnvSeq-1 HIV vaccine Envs used in this study are called CH505TF gp120, CH505w53 gp120, and CH505w78 gp120.” NCT03220724 ↗ |
| Route | Intramuscular | “administered as a 1mL IM injection into either thigh unless medically contraindicated at month 6.” NCT05182125 ↗ |